Potential use of serum CD44 as an indicator of tumour progression in acute leukemia

Hematological Oncology

Volumn 17, Issue 4, 1999, Pages 161-168

  Yokota, Akira ^a   Ishii, Genichiro ^b   Sugaya, Yoshiki ^b   Nishimura, Miki ^b   Saito, Yasushi ^b   Harigaya, Kenichi ^b  

^a CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

Acute leukemia; Serum CD44; Therapy response

Indexed keywords

HERMES ANTIGEN;

ACUTE LEUKEMIA; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0033505232     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1099-1069(199912)17:4<161::aid-hon646>3.3.co;2-p     Document Type: Article

References (36)

1. Butcher EC. The regulation of lymphocyte traffic. Curr Top Microbiol Immunol 1986; 128: 85-122.
2. Haynes BF, Telen MJ, Hale LP, Denning SM. CD44 - A molecule involved in leukocyte adherence and T-cell activation. Immunol Today 1989; 10: 423-428.
3. Miyake K, Meduna KL, Hayashi S, Ono S, Hamaoka T, Kincade PW. Monoclonal antibodies to Pgp-1/CD44 block lyrnpho-hemopoiesis in long-term bone marrow cultures. J Exptl Med 1990; 171: 477-488.
4. Jalkanen S, Bargatze RF, de los Toyos J, Butcher EC. Lymphocyte recognition of high endothelium: antibodies to distinct epitope of an 85-95 kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J Cell Biol 1987; 105: 983-999.
5. Denning SM, Le PT, Singer KH, Haynes BF. Antibodies against the CD44 p80, lymphocyte homing receptor molecule augment human peripheral blood T cell activation. J Immunol 1990; 144: 7-15.
6. Webb DSA, Shimizu Y, van Seventer GA, Shaw S, Gerrard TL. LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release. Science 1990; 249: 1295-1297.
7. Thomas L, Byers HR, Vink J, Stamenkovic I. CD44H regulates tumour cell migration on hyaluronate-coated substrate. J Cell Biol 1992; 118: 971-977.
8. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Steed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61: 1303-1313.
9. Wayner EA, Carter WG. Identification of multiple cell adhesion receptors for collagen and fibronectin in human fibrosarcoma cells possessing unique a and common ßsubunits. J Cell Biol 1987; 105: 1873-1884.
10. Carter WG, Wayner EA. Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells. J Biol Chem 1988; 263: 4193-4201.
11. Jalkanen S, Jalkanen M. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol 1992; 116: 817-825.
12. Toyama-Sorimachi N, Sorimachi H, Tobita Y, et al. A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. J Biol Chem 1995; 270: 7437-7444.
13. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992; 89: 12160-12164.
14. Tolg C, Hofmann M, Herrlich P, Ponta H. Splicing choice from ten variant exons establishes CD44 variability. Nud Acids Res 1993; 21: 1225-1229.
15. Stamenkovic I, Aruffo A, Amiot M, Steed B. The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate bearing cells. EMBO J 1991; 10: 343-348.
16. Günthert U, Hofmann M, Rudy W, et al. New variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 165: 13-24.
17. Mayer B, Jauch KW, Günthert U, et al. De novo expression of CD44 and survival in gastric cancer. Lancet 1993; 342: 1019-1022.
18. Penno MB, August JI, Baylin SB. et al. Expression of CD44 in human lung tumours. Cancer Res 1994; 54: 1381-1387.
19. Iida N, Bourguignon LY. New CD44 splice variants associated with human breast cancers. J Cell Physiol 1995; 162: 127-133.
20. Mulder JWR, Kruyt PM, Sewnath M, et al. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994; 344: 1470-1472.
21. Kainz C, Kohlberger P, Slintz G, et al. Splice variants of CD44 in human cancer stage IB to IIB. Gynecol Oncol 1995; 57: 383-387.
22. Stauder R, Eisterer W, Thaler J, Günthert U. CD44 variant isoform in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood 1995; 85: 2885-2899.
23. Yokota A, Ishii G, Sugaya Y, Nishimura M, Saito Y, Harigaya K. Expression of exon v6 containing CD44 isoforms is related with poor prognosis of acute myelocytic leukemia. Hematol Oncol 1998; 16: 131-141.
24. Bazil V, Horejsi V. Shedding of the CD44 adhesion molecule from leukocytes induced by anti-CD44 monoclonal antibody simulating the effect of a natural receptor ligand. J Immunol 1992; 149: 747-753.
25. Yang H, Binns RM. Isolation and characterization of soluble and membrane-bound porcine CD44 molecules. Immunology 1993; 78: 547 554.
26. Yu Q, Toole BP. A new alternatively spliced exon between v9 and vlO provides a molecular basis for synthesis of soluble CD44. J Biol Chem 1996; 271: 20603-20607.
27. Lucas MG, Green AM, Telen MJ. Characterization of the serum In (Lu)-related antigen: identification of a serum protein related to erythrocyte p80. Blood 1989; 73: 596-600.
28. Picker LJ, De Los Toyos J, Telen MJ, Haynes BF, Butcher EC. Monoclonal antibody against the CD44 (In (Lu)-related p80), and Pgp-1 antigens in man recognize the Hermes class of lymphocyte homing receptors. J Immunol 1989; 142: 2046 2051.
29. Haynes BF, Hale LP, Patton KL, Martin ME, McCallum RM. Measurement of an adhesion molecule as an indicator of inflammatory disease activity: up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. Arthr Rheum 1991; 34: 1434-1443.
30. Guo YJ, Liu G, Wang X, et al. Potential use of soluble CD44 in serum as indicator of tumour burden and metastasis in patients with gastric or colon cancer. Cancer Res 1994; 54: 422-426.
31. De Rossi G, Marroni P, Paganuzzi M, et al. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia. Leukemia 1997; 11: 134-141.
32. Ristamäki R, Joensuu H, Salmi M, Jalkanen S. sCD44 in malignant lymphoma: an association with treatment response. Blood 1994; 84: 238-243.
33. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institution-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813-819.
34. Greer JP, Kinney MC. Acute nonlymphocytic leukemia. In Wintrobe's Clinical Hematology, vol 2, Lee GR, Bithell TC, Forester J, Athens JW, Lukens JN (eds). Lea & Febiger: Philadelphia, London, 1993; 1920-1945.
35. Katoh S, McCarthy JB, Kincade PW. Characterization of soluble CD44 in the circulation of mice. Levels are affected by immune activity and tumour growth. J Immunol 1994; 153: 3440-3449.
36. Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Günthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994; 124: 71-82.